Tirzepatide

Tirzepatide research material, available in 10 mg, 30 mg vials. For in-vitro research only.

• Receptor occupancy calculated from signaling data showed greater engagement of the GIP receptor than of the GLP-1 receptor, which the authors describe as an imbalanced mechanism of action. [1]
• At the GLP-1 receptor the peptide favored cAMP generation over beta-arrestin recruitment and drove receptor internalization more weakly than GLP-1, while at the GIP receptor it mimicked native GIP. [1]
• Cryo-EM structures of the peptide bound to the GIP receptor and to the GLP-1 receptor showed both shared and distinct contacts, and the accompanying simulations attributed the mode of action to the fatty acid modification combined with the amino acid sequence. [2] [3]
• In mice the peptide lowered body weight and food intake more than a selective GLP-1 receptor agonist, and improved glucose tolerance by acting on both receptors. [4]

Compound

Tirzepatide

Purity

99.30% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg · 30 mg

Catalog / lot

RV-0045 / RV-24-0045-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.